公开(公告)号：US20220064316A1

公开(公告)日：2022-03-03

申请号：US17359211

申请日：2021-06-25

Applicant: The Trustees of the University of Pennsylvania ,  Novartis AG

Inventor： Jennifer Brogdon ,  Eugene Choi ,  Hilmar Erhard Ebersbach ,  David Jonathan Glass ,  Heather Huet ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Celeste Richardson ,  Marco Ruella ,  Reshma Singh ,  Yongqiang Wang ,  Qilong Wu

IPC: C07K16/28 ,  C07K14/725 ,  C07K19/00 ,  A61P35/00 ,  C07H21/04 ,  C07K14/715 ,  A61K39/395 ,  A61K38/17 ,  C12N5/00 ,  C12N15/63 ,  C07K14/705 ,  A61K35/12

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20190263914A1

公开(公告)日：2019-08-29

申请号：US16210480

申请日：2018-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74 ,  C12N9/90 ,  A61K35/17 ,  C07K14/71 ,  C12N9/12

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US11591404B2

公开(公告)日：2023-02-28

申请号：US16884867

申请日：2020-05-27

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  C07K16/24 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

公开(公告)号：US08722621B2

公开(公告)日：2014-05-13

申请号：US13664055

申请日：2012-10-30

Applicant: Novartis AG

Inventor： David Jonathan Glass ,  Mara Fornaro

IPC: A61K38/30

CPC classification number: C07K14/475 ,  A61K38/30 ,  C07K14/65

Abstract: The invention relates to stabilized polypeptides having an IGF-1 sequence and an Ea peptide sequence, where the natural physiological cleavage of the Ea peptide from the IGF-1 is prevented.

Abstract translation: 本发明涉及具有IGF-1序列和Ea肽序列的稳定多肽，其中防止了来自IGF-1的Ea肽的天然生理切割。

公开(公告)号：US12091424B2

公开(公告)日：2024-09-17

申请号：US17499433

申请日：2021-10-12

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew William Patterson ,  Silvio Roggo ,  Tea Shavlakadze

IPC: C07D498/18 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/10 ,  A61P35/00 ,  A61P37/00 ,  C07F9/6561

CPC classification number: C07D498/18 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/10 ,  A61P35/00 ,  A61P37/00 ,  C07F9/6561

Abstract: The disclosure relates to compounds of formula (I)




and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

公开(公告)号：US20210172020A1

公开(公告)日：2021-06-10

申请号：US16986943

申请日：2020-08-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Felipe Bedoya ,  Hans Bitter ,  Jennifer Brogdon ,  Corin Dorfmeier ,  Abhishek Garg ,  David Jonathan Glass ,  Joan Mannick ,  Jan J. Melenhorst ,  Michael C. Milone ,  Leon Murphy ,  Elena Orlando ,  Nicholas Wilcox

IPC: C12Q1/6886 ,  G01N33/574 ,  C12N5/0783 ,  A61K39/00

Abstract: Cancer biomarkers and methods of using them are disclosed.

公开(公告)号：US10774388B2

公开(公告)日：2020-09-15

申请号：US15517597

申请日：2015-10-07

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Felipe Bedoya ,  Hans Bitter ,  Jennifer Brogdon ,  Corin Dorfmeier ,  Abhishek Garg ,  David Jonathan Glass ,  Joan Mannick ,  Jan J. Melenhorst ,  Michael Milone ,  Leon Murphy ,  Elena Orlando ,  Nicholas Wilcox

IPC: C12Q1/6886 ,  G01N33/574 ,  C12N5/0783 ,  A61K39/00

Abstract: Cancer biomarkers and methods of using them are disclosed.

公开(公告)号：US20190153061A1

公开(公告)日：2019-05-23

申请号：US16197565

申请日：2018-11-21

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Eugene Choi ,  Hilmar Erhard Ebersbach ,  David Jonathan Glass ,  Heather Huet ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Celeste Richardson ,  Marco Ruella ,  Reshma Singh ,  Yongqiang Wang ,  Qilong Wu

IPC: C07K14/705 ,  C07K16/28 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00 ,  A61K35/12 ,  A61K38/17

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20230026049A1

公开(公告)日：2023-01-26

申请号：US17661207

申请日：2022-04-28

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74 ,  C12N9/90 ,  C12N9/12 ,  C07K14/71 ,  A61K31/436 ,  A61K35/17

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20220064185A1

公开(公告)日：2022-03-03

申请号：US17414696

申请日：2019-12-17

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew W. Patterson ,  Silvio Roggo ,  Tea Shavlakadze ,  Patrik Zueger

IPC: C07D498/18 ,  A61K45/06 ,  A61K31/436

Abstract: The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.